The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Spravato has been approved since 2019 for TRD ... an intranasal formulation of racemic ketamine.

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

This is because the Food and Drug Administration (FDA) only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine.

So SPRAVATO is indicated for treatment resistant depression. It is esketamine. It's a single enantiomer of ketamine. It's an intranasally administered compound. It was approved in 2019 for ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

The nasal variant of ketamine, esketamine, was developed by Johnson & Johnson Pharmaceuticals under the name brand Spravato; it’s the only type of ketamine approved by the FDA for treatment ...